Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alteplase + argatroban
- Development stage
- Unknown
- Lead developer
- Hui-Sheng Chen
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of **alteplase** and **argatroban** is a therapeutic regimen being evaluated for the treatment of acute posterior circulation infarction. Alteplase is a recombinant tissue plasminogen activator (rt-PA) that functions as a thrombolytic agent by converting plasminogen to plasmin, which subsequently degrades fibrin clots. Argatroban is a small-molecule direct thrombin inhibitor that reversibly binds to the thrombin active site, preventing fibrin formation and platelet aggregation. This combination is the focus of the Phase 4 **AR-PCI** (Argatroban Plus r-tPA for Posterior Circulation Infarction) trial led by researcher **Hui-Sheng Chen**. The study aims to determine if adding argatroban to standard alteplase therapy can improve clinical outcomes and vessel recanalization rates in patients with ischemic strokes involving the posterior circulation, without significantly increasing the risk of hemorrhage.
- Brand names
- ActivaseCathfloActilyseArgatraArganovaExembol
- Other names
- rt-PA + argatrobanrecombinant tissue plasminogen activator + argatroban
02
Targets
F2 (Thrombin)PLG (Plasminogen)
Beyond the preview
Go deeper on alteplase + argatroban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alteplase + argatroban.